Some Benefit for Curcuminoids in Knee Osteoarthritis

This article originally appeared here.
Share this content:
Some Benefit for Curcuminoids in Knee Osteoarthritis
Some Benefit for Curcuminoids in Knee Osteoarthritis

FRIDAY, May 26, 2017 (HealthDay News) -- Curcuminoids seem beneficial for knee osteoarthritis (OA), although they are less effective for pain relief than ibuprofen, according to a review and meta-analysis published online May 4 in the International Journal of Rheumatic Diseases.

Igho J. Onakpoya, M.D., from the University of Oxford in the United Kingdom, and colleagues reviewed data from randomized controlled trials that examined the effectiveness of orally-administered curcuminoids in OA in adults. Data were included from seven studies conducted in Asia, with 797 participants with primarily knee OA.

The overall risk of bias in the studies was moderate. The researchers found that curcuminoids correlated with significantly reduced knee pain (standardized mean difference, − 3.45) and improved quality of life (mean difference, −2.69) compared with placebo. Compared with ibuprofen, curcuminoids had significantly fewer effects on pain relief, knee stiffness, and physical function. Curcuminoids also correlated with significant improvements in Western Ontario and McMaster Universities Arthritis Index total scores and with significant reductions in rescue medication use. There were no serious adverse events.

"Curcuminoids may have some beneficial effects on knee pain and quality of life in patients with knee OA," the authors write. "However, they are less effective at relieving pain compared with ibuprofen."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »